Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. Reply to Holden SE, Bannister CA, Currie CJ [letter]
| Autor: | Søren Friis, Bendix Carstensen, Kristina Ranc, Marit E. Jørgensen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Diabetes duration Glucose lowering Entire population medicine.medical_specialty education.field_of_study business.industry Endocrinology Diabetes and Metabolism Population Cancer Type 2 diabetes medicine.disease Surgery Diabetes Complications Diabetes Mellitus Type 2 Neoplasms Diabetes mellitus Internal Medicine medicine Humans Female Observational study Psychiatry education business |
| Zdroj: | Diabetologia. 57:2003-2004 |
| ISSN: | 1432-0428 0012-186X |
| DOI: | 10.1007/s00125-014-3329-2 |
| Popis: | To the Editor: In the light of the general comments made about our article [1] by Holden et al [2], we acknowledge that we did not specify with sufficient emphasis that our study was based on the entire population of cancer patients in Denmark, that is to say, it was essentially demographic in its nature. The uncertainty about the underlying study base has led Holden et al to raise concerns about the lack of characterisation of the cohorts. Unlike clinical observational studies of patients from clinical databases, there is only limited clinical information on the general population of all cancer patients in Denmark, and hence it is not possible to provide a detailed clinical characterisation of the population. On the other hand, our study gives an overall picture of how the entire population of cancer patients fare in relation to their diabetes status. The following are our replies to the specific questions raised by Holden et al |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink